SAN DIEGO, Nov. 06, 2017 -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will present at the following upcoming investor conferences:
Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 9, 2017, Presentation at 2:30pm EST
Westin Grand Central Hotel
Webcast Available at: http://wsw.com/webcast/canaccord28/obln/
Stifel Healthcare Conference
Tuesday, November 14, 2017, Presentation at 8:45am EST
Lotte New York Palace Hotel
Webcast Available at: http://wsw.com/webcast/stifel10/obln/
Live audio webcasts of the presentation can be accessed through the links above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
[email protected]
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
[email protected]


Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
How Marco Pharma International Preserves German Homeopathic Traditions in America
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 



